Navigation Links
VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
Date:11/12/2009

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... Minn., March 10 Here are highlights from the March ... cite this publication as often as you wish. Reprinting is ... attribution is required. Include the following ... www.HealthLetter.MayoClinic.com or call toll-free for subscription ...
... Avineuro Pharmaceuticals, Inc. announced today an initiation of ... selective small molecule antagonist of 5-HT6 receptor for treatment ... expected to be available in April 2009. Based on ... advance AVN-211 into Phase II clinical trials in Q2 ...
Cached Medicine Technology:March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 2March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 3March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 4March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 5
(Date:11/27/2014)... New Albany, IN (PRWEB) November 27, 2014 ... dental implant clinic, has a few oral health tips ... Dr. Receveur, who offers Louisville and New Albany affordable ... mountains of foods high in starch and sugar. While the ... practice has some helpful tips for how patients can enjoy ...
(Date:11/27/2014)... Burnsville MN (PRWEB) November 27, 2014 ... manufacturer of office ergonomics equipment , has announced ... partnership with Commercial Office Environments. The partnership will ... for office furnishings location. , In addition to ... the new dealer partnership promotes HealthPostures' products with ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Allowing children to ... even during school, helps give children responsibility, ownership, boosts self-esteem, ... , Now, the real question is, how do ... a secret? According to a study published by Child Development ... have a dramatic effect on a child’s willingness to lend ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... of laughter as we enjoy the ugly sweater contest." ... from scratch. " It was a sight to see. ... ridiculous enough, the Christmas balls were faces of the staff ... in participating this year, it's simple to get in on ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, ... announced online reputation management service. , The ... study about the world of internet marketing and algorithms ... , Ethane Web Technologies does not work with ... analyzes the project to reach a conclusion what will ...
Breaking Medicine News(10 mins):Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces Online Reputation Management Service 2
... a waiting list, can reduce problems with recurring low back ... Many people suffer with low back pain, and most ... find that their work, everyday and leisure activities are limited ... treatment, it is important that the pain be treated at ...
... Food and Drug Administration (FDA) approval of a brain aneurysm ... Jefferson Hospital for Neuroscience (JHN) to offer advanced ... otherwise have limited, effective options. "With this FDA approval, ... tool to block and shrink these types of aneurysms, saving ...
... Indiana soon will partner with colleagues in Ohio ... working across state lines to advance research on ... program, supported by the Indiana Clinical and Translational ... across the region, including Indiana University Health Riley ...
... Prozac: new drug offers hope for depression ... from depression, and though the symptoms might be ... incompletely understood. Research suggests that aberrant signaling by ... its receptor TrkB, may contribute to anxiety and ...
... Vancouver,s Downtown Eastside dropped by 35 per cent after ... facility, according a new study by researchers at the ... for Excellence in HIV/AIDS. Published today in The ... assess the impact of supervised injection sites on overdose ...
... Psychologists are offering new insight and solutions ... with the environmental, economic and health impacts already taking ... issue of American Psychologist , the American Psychological ... for and in many cases is already affecting ...
Cached Medicine News:Health News:Immediate treatment can alleviate future back problems 2Health News:FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool 2Health News:Children's doctors team up across state lines to fight disease 2Health News:JCI online early table of contents: April 18, 2011 2Health News:JCI online early table of contents: April 18, 2011 3Health News:JCI online early table of contents: April 18, 2011 4Health News:JCI online early table of contents: April 18, 2011 5Health News:JCI online early table of contents: April 18, 2011 6Health News:JCI online early table of contents: April 18, 2011 7Health News:Overdose deaths down 35 percent after opening of Vancouver's supervised injection site: UBC-BC-CfE study 2Health News:Climate change psychology: Coping and creating solutions 2Health News:Climate change psychology: Coping and creating solutions 3
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: